MX2024010081A - Compuestos de pirazolilo como activadores del canal de potasio dependientes de voltaje 7 (kv7). - Google Patents
Compuestos de pirazolilo como activadores del canal de potasio dependientes de voltaje 7 (kv7).Info
- Publication number
- MX2024010081A MX2024010081A MX2024010081A MX2024010081A MX2024010081A MX 2024010081 A MX2024010081 A MX 2024010081A MX 2024010081 A MX2024010081 A MX 2024010081A MX 2024010081 A MX2024010081 A MX 2024010081A MX 2024010081 A MX2024010081 A MX 2024010081A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- activators
- voltage
- potassium channel
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263313212P | 2022-02-23 | 2022-02-23 | |
| PCT/US2023/063113 WO2023164537A1 (en) | 2022-02-23 | 2023-02-23 | Pyrazolyl compounds as kv7 channel activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024010081A true MX2024010081A (es) | 2024-08-27 |
Family
ID=87766732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024010081A MX2024010081A (es) | 2022-02-23 | 2023-02-23 | Compuestos de pirazolilo como activadores del canal de potasio dependientes de voltaje 7 (kv7). |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250171430A1 (enExample) |
| EP (1) | EP4482486A4 (enExample) |
| JP (1) | JP2025507543A (enExample) |
| KR (1) | KR20240150500A (enExample) |
| CN (1) | CN118678954A (enExample) |
| AU (1) | AU2023225967A1 (enExample) |
| CA (1) | CA3244850A1 (enExample) |
| IL (1) | IL314555A (enExample) |
| MX (1) | MX2024010081A (enExample) |
| WO (1) | WO2023164537A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202528310A (zh) * | 2023-09-20 | 2025-07-16 | 美商深蘋果治療股份有限公司 | 經取代胺化合物，組合物及使用方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3098075A (en) * | 1956-02-10 | 1963-07-16 | Ciba Geigy Corp | New pyrazolo-pyrimidines |
| ATE410161T1 (de) * | 2003-05-02 | 2008-10-15 | Elan Pharm Inc | 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen |
| ES2351274T3 (es) * | 2007-06-06 | 2011-02-02 | Torrent Pharmaceuticals Ltd | Nuevos compuestos. |
| UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| CN103619171B (zh) * | 2010-11-03 | 2015-11-25 | 陶氏益农公司 | 杀虫组合物和与其相关的方法 |
| US9067894B1 (en) * | 2013-03-07 | 2015-06-30 | Vanderbilt University | Compound, composition, and method of activating GIRK potassium channel and use of same for treating conditions of interest |
| CN107406380B (zh) * | 2015-02-04 | 2020-04-28 | 上海海雁医药科技有限公司 | 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途 |
| WO2016164703A1 (en) * | 2015-04-09 | 2016-10-13 | Eisai R & D Management Co., Ltd. | Fgfr4 inhibitors |
| EP3558992A4 (en) * | 2016-12-15 | 2020-12-02 | ONO Pharmaceutical Co., Ltd. | TREK CHANNEL ACTIVATOR (K + CHANNELS ASSOCIATED WITH TWIK) |
| CN114127058B (zh) * | 2019-07-04 | 2024-06-25 | 深圳国顺康医药科技有限公司 | 一种杂环化合物、其药物组合物及用途 |
| CN110627725B (zh) * | 2019-10-14 | 2022-10-18 | 遵义医科大学 | 一种4-取代5-二氟甲基-3-硝基-1h-吡唑类化合物及其制备方法与应用 |
| JP2021121582A (ja) * | 2020-01-31 | 2021-08-26 | クミアイ化学工業株式会社 | ５−（ピラゾール−５−イル）安息香酸アミド誘導体及び有害生物防除剤 |
| EP4482487A4 (en) * | 2022-02-23 | 2026-04-15 | Biohaven Therapeutics Ltd | PYRAZOLYL COMPOUNDS USED AS KV7 CHANNEL ACTIVATORS |
| CN118695860A (zh) * | 2022-02-23 | 2024-09-24 | 拜奥海芬治疗学有限公司 | 作为kv7通道激活剂的吡唑基化合物 |
-
2023
- 2023-02-23 WO PCT/US2023/063113 patent/WO2023164537A1/en not_active Ceased
- 2023-02-23 KR KR1020247031499A patent/KR20240150500A/ko active Pending
- 2023-02-23 MX MX2024010081A patent/MX2024010081A/es unknown
- 2023-02-23 US US18/839,860 patent/US20250171430A1/en active Pending
- 2023-02-23 EP EP23760909.4A patent/EP4482486A4/en active Pending
- 2023-02-23 CA CA3244850A patent/CA3244850A1/en active Pending
- 2023-02-23 IL IL314555A patent/IL314555A/en unknown
- 2023-02-23 JP JP2024547297A patent/JP2025507543A/ja active Pending
- 2023-02-23 CN CN202380021420.5A patent/CN118678954A/zh active Pending
- 2023-02-23 AU AU2023225967A patent/AU2023225967A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118678954A (zh) | 2024-09-20 |
| KR20240150500A (ko) | 2024-10-15 |
| CA3244850A1 (en) | 2023-08-31 |
| EP4482486A1 (en) | 2025-01-01 |
| WO2023164537A1 (en) | 2023-08-31 |
| US20250171430A1 (en) | 2025-05-29 |
| EP4482486A4 (en) | 2026-04-15 |
| AU2023225967A1 (en) | 2024-08-29 |
| IL314555A (en) | 2024-09-01 |
| JP2025507543A (ja) | 2025-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001153A (es) | Composiciones y metodos de uso de los activadores del canal kv7. | |
| AR092857A1 (es) | Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas | |
| MX2021014911A (es) | Lípidos sintéticos para administración de arnm. | |
| PH12023552741A1 (en) | Psilocybin Compositions, Methods Of Making And Methods Of Using The Same | |
| PE20221280A1 (es) | Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos | |
| CO2019000943A2 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
| AR058679A1 (es) | Preparacion farmaceutica que contiene meloxicam | |
| MX2019010757A (es) | Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor. | |
| EA201892657A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| MX2024010078A (es) | Compuestos de pirazolilo como activadores del canal de potasio dependientes de voltaje 7 (kv7). | |
| MX383077B (es) | Composiciones farmaceuticas para la administracion intraocular que comprenden un agente antibacteriano y un agente antiinflamatorio. | |
| CO2024005250A2 (es) | Formulaciones y sistemas de erdafitinib para administración intravesical | |
| JOP20230089A1 (ar) | مثبطات إنترليوكين-17 | |
| CL2022001102A1 (es) | Métodos para el tratamiento de trastornos depresivos. | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| MX2024010568A (es) | Compuestos terapeuticos, formulaciones y uso de estos. | |
| CL2022000639A1 (es) | Métodos de uso para activadores de canal kv7 | |
| CL2021001621A1 (es) | Formulaciones orales de branaplam | |
| CO2025007025A2 (es) | Formulaciones orales compactables de ibutamoren | |
| WO2025137652A3 (en) | Compositions comprising radiprodil and the use of radiprodil in the treatment of epileptic or neurobehavioral disorders | |
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| MX2021008188A (es) | Compuestos de anandamida. | |
| CL2022001426A1 (es) | Formulación pediátrica de liberación inmediata del abridor de canales de potasio ezogabina | |
| MX2024001744A (es) | Formulaciones de radiprodil. | |
| UY27947A1 (es) | Prófarmaco ihnibidor de beta-lactamasa |